Neoadjuvant Nivolumab–Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study

Abstract

Introduction: Neoadjuvant chemotherapy (NAC) is standard for muscle-invasive bladder cancer (MIBC), yet many patients are platinum-ineligible. We compared outcomes of neoadjuvant nivolumab plus ipilimumab versus platinum-based NAC